Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of BGG492 adjunctive therapy in adults with partial-onset seizures
2010-021448-17Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selurampanel in epilepsy and Focal onset seizure, sponsored by Novartis. Primary endpoints: Seizure frequency and seizure types, Long-term safety and tolerability and 1 more. Started Jan 2011; status: completed.
02
Drugs
selurampanel
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on 2010-021448-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021448-17.